Cargando…

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

OBJECTIVES: To determine the safety, efficacy and pharmacokinetic (PK) profile of a pre-mixed depot formulation of leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg for up to 1 year of treatment for subjects with advanced prostate cancer. PATIENTS AND METHODS: In this open-label, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shore, Neal, Mincik, Ivan, DeGuenther, Mark, Student, Vladimir, Jievaltas, Mindaugas, Patockova, Jitka, Simpson, Kelle, Hu, Chu-Hsuan, Huang, Shih-Tsung, Li, Yuhua, Lee, Yisheng, Chien, Ben, Mao, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954127/ https://www.ncbi.nlm.nih.gov/pubmed/30941562 http://dx.doi.org/10.1007/s00345-019-02741-7

Ejemplares similares

Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022)

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
por: Vurallı, Doğuş, et al.
Publicado: (2020)

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023)

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies
por: Spitz, Aaron, et al.
Publicado: (2016)

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study
por: Lee, Peter A, et al.
Publicado: (2011)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
por: Shore, Neal D., et al.
Publicado: (2023)

Amyloid as a Depot for the Formulation of Long-Acting Drugs
por: Maji, Samir K, et al.
Publicado: (2008)

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer
por: Saad, Fred, et al.
Publicado: (2023)

Myocardial Infarction in a Premenopausal Woman on Leuprolide Therapy
por: Perez, Irving E., et al.
Publicado: (2015)

Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis
por: Hill, Amanda M., et al.
Publicado: (2018)

SUN-421 Leuprolide Injection Induced Pituitary Apoplexy
por: Jaggi, Shirin, et al.
Publicado: (2019)

Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate
por: Ahad, Abdul, et al.
Publicado: (2017)

Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen)
por: Deka, Kamala, et al.
Publicado: (2015)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
por: Metbulut, Azize Pınar, et al.
Publicado: (2021)

Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020)

Testosterone-Mediated Aggression in Angelman Syndrome Treated With Leuprolide and Orchiectomy
por: Anderson, Danyon J, et al.
Publicado: (2022)

PMON70 Systemic Delivery of Leuprolide via Oral Administration
por: Shangold, Gary, et al.
Publicado: (2022)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

Injectable Lipid-Based Depot Formulations: Where Do We Stand?
por: Rahnfeld, Lisa, et al.
Publicado: (2020)

Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
por: Kadivar, Ali, et al.
Publicado: (2015)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
por: Lazaridou, Maria, et al.
Publicado: (2020)

Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model
por: Zhu, Zejiang, et al.
Publicado: (2022)

Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
por: Ahad, Abdul, et al.
Publicado: (2022)

Delayed Oral Estradiol Combined with Leuprolide Increases Endometriosis-Related Pain
por: Hurst, Bradley S., et al.
Publicado: (2000)

Formulation and Evaluation of Pharmaceutically Equivalent Parenteral Depot Suspension of Methyl Prednisolone Acetate
por: Alam, A., et al.
Publicado: (2009)

Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use
por: Schreiner, Viktoria, et al.
Publicado: (2020)

Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
por: Mietzner, Raphael, et al.
Publicado: (2020)

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design
por: Freedland, Stephen J, et al.
Publicado: (2021)

The effect of complete transurethral resection of the prostate on symptoms, quality of life, and voiding function improvement
por: Milonas, Daimantas, et al.
Publicado: (2015)

Significance of Time Until PSA Recurrence After Radical Prostatectomy Without Neo- or Adjuvant Treatment to Clinical Progression and Cancer-Related Death in High-Risk Prostate Cancer Patients
por: Venclovas, Zilvinas, et al.
Publicado: (2019)

Age and aggressiveness of prostate cancer: analysis of clinical and pathological characteristics after radical prostatectomy for men with localized prostate cancer
por: Milonas, Daimantas, et al.
Publicado: (2019)

Development and Validation of a Dissolution Test for Meloxicam and Pridinol Mesylate from Combined Tablet Formulation
por: Vignaduzzo, S. E., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_etauhtaojmt43mmgp9fo2vrq71